BIOCRYST PHARMACEUTICALS, INC. Acquisitions, Net of Cash Acquired
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Acquisitions, Net of Cash Acquired of $489.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2026-06-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2026-03-31 was $489.48M.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2025-06-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2025-03-31 was $0.00.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $489.48M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $489.48M 10-Q · filed 2026-05-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |